Erstellt am 06 Mar 2023 20:33
Zuletzt geändert: 30 May 2024 16:32
Pubmed
- Suche: ("tumor treating fields"[Title/Abstract] OR "alternating electric fields"[Title/Abstract] OR "ttf"[Title/Abstract] OR "optune"[Title/Abstract] OR "alternating electromagnetic fields"[Title/Abstract])
- Suche: ("tumor treating fields"[Title/Abstract] OR "alternating electric fields"[Title/Abstract] OR "ttf"[Title/Abstract] OR "optune"[Title/Abstract] OR "alternating electromagnetic fields"[Title/Abstract]) AND "glioma"[Title/Abstract]
- Suche: ("tumor treating fields"[Title/Abstract] OR "alternating electric fields"[Title/Abstract] OR "ttf"[Title/Abstract] OR "optune"[Title/Abstract] OR "alternating electromagnetic fields"[Title/Abstract]) AND "astrocytoma"[Title/Abstract]
- Suche: (((("brain"[Title/Abstract] AND ("metastatic"[Title/Abstract] OR "Metastases"[Title/Abstract]) AND ("tumor treating fields"[Title/Abstract] OR "alternating electric fields"[Title/Abstract] OR "ttf"[Title/Abstract] OR "optune"[Title/Abstract] OR "alternating electromagnetic fields"[Title/Abstract])) NOT "time to treatment failure"[All Fields]) NOT "thyroid transcription factor"[Title/Abstract]) NOT "ttf-1"[Title/Abstract]
- Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer; Novocure Press release, 01.03.23:
Novocure (NASDAQ: NVCR) today announced that the final patient has enrolled in the pivotal METIS study evaluating the efficacy of Tumor Treating Fields (TTFields) therapy following stereotactic radiosurgery (SRS) for treatment of patients with brain metastases resulting from non-small cell lung cancer (NSCLC).
Final data from the METIS study anticipated in 2024.
- Mohile NA, Messersmith H, Gatson NT, Hottinger AF, Lassman A, Morton J, Ney D, Nghiemphu PL, Olar A, Olson J, Perry J, Portnow J, Schiff D, Shannon A, Shih HA, Strowd R, van den Bent M, Ziu M, Blakeley J. Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. J Clin Oncol. 2022 Feb 1;40(4):403-426. doi: 10.1200/JCO.21.02036. Epub 2021 Dec 13. PMID: 34898238.
ASCO and the Society for Neuro-Oncology convened an Expert Panel and conducted a systematic review of the literature.
People with astrocytoma, IDH-mutant, CNS WHO grade 4 may follow recommendations for either astrocytoma, IDH-mutant, 1p19q non-codeleted CNS WHO grade 3 or glioblastoma, IDH-wildtype, CNS WHO grade 4. Concurrent TMZ and RT should be offered to patients with newly diagnosed glioblastoma, IDH-wildtype, CNS WHO grade 4 followed by 6 months of adjuvant TMZ. Alternating electric field therapy, approved by the US Food and Drug Administration, should be considered for these patients. Bevacizumab is not recommended.
Alle medizinischen Aussagen und Informationen in diesem Wiki dienen nicht der individuellen Beratung und können und sollen eine persönliche fachliche ärztliche oder sonstige Beratung nicht ersetzen! Auch erheben die hier gemachten Aussagen keinen Anspruch auf Richtigkeit oder Vollständigkeit. Dies ist keine Gesundheitsberatungsseite und auch keine Sozialberatungsseite!
Neue Seite anlegen